Who are Valium + Akineton + Dehydrobenzperidol + Atropine sulfate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/valium-akineton-dehydrobenzperidol-atropine-sulfate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate (Valium + Akineton + Dehydrobenzperidol + Atropine sulfate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination sedative-antipsychotic. Area: Psychiatry/Neurology.

marketed Combination sedative-antipsychotic GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Valium + Akineton + Dehydrobenzperidol + Atropine sulfate (Valium + Akineton + Dehydrobenzperidol + Atropine sulfate) — Universitaire Ziekenhuizen KU Leuven. This combination drug produces sedation, muscle relaxation, and antipsychotic effects through multiple central nervous system depressants and anticholinergic agents acting simultaneously.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Valium + Akineton + Dehydrobenzperidol + Atropine sulfate TARGET	Valium + Akineton + Dehydrobenzperidol + Atropine sulfate	Universitaire Ziekenhuizen KU Leuven	marketed	Combination sedative-antipsychotic	GABA-A receptor, dopamine D2 receptor, muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination sedative-antipsychotic class)

Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Valium + Akineton + Dehydrobenzperidol + Atropine sulfate — Competitive Intelligence Brief. https://druglandscape.com/ci/valium-akineton-dehydrobenzperidol-atropine-sulfate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab